First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction [Clinical Trials]
Conclusion
Monthly infusions of NEOD001 were safe and well tolerated. Recommended future dosing was 24 mg/kg. Organ response rates compared favorably with those reported previously for chemotherapy. A phase II expansion is ongoing. A global phase III study (NCT02312206) has been initiated. Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Gertz, Landau, Comenzo, Seldin, Weiss, Zonder, Merlini, Schonland, Walling, Kinney, Koller, Schenk, Guthrie, Liedtke Tags: Phase I and Clinical Pharmacology Clinical Trials Source Type: research
More News: Amyloidosis | Cancer & Oncology | Chemotherapy | Clinical Trials | Cough | Drugs & Pharmacology | Hematology | Respiratory Medicine | Study | Toxicology